119 related articles for article (PubMed ID: 8846009)
1. Quality assurance and good manufacturing practices for processing hematopoietic progenitor cells.
McCullough J
J Hematother; 1995 Dec; 4(6):493-501. PubMed ID: 8846009
[TBL] [Abstract][Full Text] [Related]
2. Quality assurance and standards in hematopoietic progenitor processing.
Bennett ST; Johnson NL; Lasky LC
J Clin Apher; 1992; 7(3):138-44. PubMed ID: 1363102
[TBL] [Abstract][Full Text] [Related]
3. Regulation of hematopoietic stem cell processing and transplantation.
Rowley SD
Int J Hematol; 2002 Apr; 75(3):237-45. PubMed ID: 11999350
[TBL] [Abstract][Full Text] [Related]
4. Good manufacturing practice production of human stem cells for somatic cell and gene therapy.
Bosse R; Singhofer-Wowra M; Rosenthal F; Schulz G
Stem Cells; 1997; 15 Suppl 1():275-80. PubMed ID: 9368351
[TBL] [Abstract][Full Text] [Related]
5. A European reference protocol for quality assessment and clinical validation of autologous haematopoietic blood progenitor and stem cell grafts.
Serke S; Johnsen HE
Bone Marrow Transplant; 2001 Mar; 27(5):463-70. PubMed ID: 11313679
[TBL] [Abstract][Full Text] [Related]
6. Quality assessment of autologous hematopoietic blood progenitor and stem cell grafting: a prospective registration study.
Johnsen HE; Lanza F
J Biol Regul Homeost Agents; 2002; 16(4):272-88. PubMed ID: 12597644
[No Abstract] [Full Text] [Related]
7. Microbial contamination of cellular products for hematolymphoid transplantation therapy: assessment of the problem and strategies to minimize the clinical impact.
Lowder JN; Whelton P
Cytotherapy; 2003; 5(5):377-90. PubMed ID: 14578100
[TBL] [Abstract][Full Text] [Related]
8. Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program.
Bolan CD; Hartzman RJ; Perry EH; Trainor L; Miller J; Miller R; Hanley L; Chitphakdithai P; King RJ
Biol Blood Marrow Transplant; 2008 Sep; 14(9 Suppl):23-8. PubMed ID: 18721777
[TBL] [Abstract][Full Text] [Related]
9. Regulation of placental and umbilical cord blood stem cells.
Wagner JE
J Hematother; 1997 Feb; 6(1):1-3. PubMed ID: 9112212
[No Abstract] [Full Text] [Related]
10. Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors.
Shpall EJ
J Hematother; 1997 Aug; 6(4):287-9. PubMed ID: 9377066
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow processing: the role of standardized practice.
Ross RE; Jeter EK
Prog Clin Biol Res; 1994; 389():737-45. PubMed ID: 7700940
[No Abstract] [Full Text] [Related]
12. [Analysis of the implementation of a Joint Accreditation Committee of the International Society for Cellular Therapy and European Group for Blood and Marrow Transplantation acreditation in a clinical program of hematopoietic progenitor cell transplantation].
Ferrà C; Jiménez-Lorenzo MJ; Feliu E; Ribera JM;
Med Clin (Barc); 2011 Jun; 137(3):126-30. PubMed ID: 20303546
[No Abstract] [Full Text] [Related]
13. Ex-vivo purging of hematopoietic progenitor cells.
de Lima M; Shpall EJ
Curr Hematol Rep; 2004 Jul; 3(4):257-64. PubMed ID: 15217555
[TBL] [Abstract][Full Text] [Related]
14. Process validation.
Preti RA
Cytotherapy; 1999; 1(6):481-3. PubMed ID: 20426548
[TBL] [Abstract][Full Text] [Related]
15. Validation of a single-platform method for hematopoietic CD34+ stem cells enumeration according to accreditation procedure.
Massin F; Huili C; Decot V; Stoltz JF; Bensoussan D; Latger-Cannard V
Biomed Mater Eng; 2015; 25(1 Suppl):27-39. PubMed ID: 25538053
[TBL] [Abstract][Full Text] [Related]
16. Australasian CD34+ quality assurance program and rationale for the clinical utility of the single-platform method for CD34+ cell enumeration.
Chang A; Raik E; Marsden K; Ma DD
Cytotherapy; 2004; 6(1):50-61. PubMed ID: 14985167
[TBL] [Abstract][Full Text] [Related]
17. Stem cells: what's happening? Focus on quality assurance, GMP and regulatory aspects.
Seghatchian MJ
Transfus Sci; 1998 Jun; 19(2):191-2. PubMed ID: 10187043
[No Abstract] [Full Text] [Related]
18. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
Warkentin PI;
Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
[TBL] [Abstract][Full Text] [Related]
19. Reduction of marrow hematopoietic progenitor and stem cell content is not sufficient for enhanced syngeneic engraftment.
Robinson S; van Os R; Sheridan T; Mauch P
Stem Cells; 2000; 18(2):93-101. PubMed ID: 10742381
[TBL] [Abstract][Full Text] [Related]
20. Development of a clinically applicable high-speed flow cytometer for the isolation of transplantable human hematopoietic stem cells.
Sasaki DT; Tichenor EH; Lopez F; Combs J; Uchida N; Smith CR; Stokdijk W; Vardanega M; Buckle AM; Chen B
J Hematother; 1995 Dec; 4(6):503-14. PubMed ID: 8846010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
